Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: sustained benefits + 3,270 + therapy  Related to the article below (Last Update: 8/5/2008)

LSB Corporation Announces Second Quarter 2008 and Year-to-Date ...
Trading Markets (press release), CA - Jul 24, 2008
The increase in the provision for loan losses in 2008 is due to the continued and sustained corporate and retail loan growth rather than deterioration of ...LSBX - OTC:CMTX
Bridge Bancorp, Inc. Reports Second Quarter 2008 Results; Strong ...
istockAnalyst.com, OR - Jul 18, 2008
"The continued and sustained deposit growth evidences the success of our branch expansion initiatives, and more importantly reflects the opportunities ...BDGE - KIDS
Source: Google News

Neurofeedback: An Alternative and Efficacious Treatment for Attention Deficit Hyperactivity Disorder -
DJ Fox, DF Tharp, LC Fox - Applied Psychophysiology and Biofeedback, 2005 - Springer
... It appears that stimulant therapy ?would appear to constitute a type of ... Several studies
have shown that long-term sustained benefits of EEG biofeedback or ...

Cellular vaccine therapy for cancer -
AC Armstrong, D Eaton, JC Ewing - erv, 2002 - Future Drugs
... led to an interest in the exploitation of DCs for tumor vaccine therapy. ... of antigen
for presenta- tion and therefore lead to more sustained antigen expression. ...

The search for disease modification in moderate to severe Alzheimer disease A critical review of … -
MR Farlow - Neurology, 2005 - AAN Enterprises
... Proc Natl Acad Sci USA 1994;91:3270?3274. ... in moderately severe Alzheimer?s disease:
does early initiation of therapy offer sustained benefits? ...

Current Advances in CFS Therapy -
P De Becker, NR McGregor, K De Smet, K De Meirleir - Chronic Fatigue Syndrome: A Biological Approach, 2002 - books.google.com
... therapy is not recommended in CFS, partly based on expense, tolerability, available
data showing limited efficacy, and transient nature of the benefits. ...

Antioxidant agents.
F Only, MR Farlow - NEUROLOGY, 2005 - AAN Enterprises
... Proc Natl Acad Sci USA 1994;91:3270?3274. ... in moderately severe Alzheimer?s disease:
does early initiation of therapy offer sustained benefits? ...
-

Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid … -
BE Garfield, T Krahl, S Appel, SM Cooper, M Rinc?n - Clinical Immunology, 2005 - Elsevier
... The mechanism or mechanisms that are responsible for sustained improvement are not
well ... could account for some of the long-term benefit found with ... 3261?3270. ...

Manipulation of the Cervical Spine: Risks and Benefits -
RP Di Fabio - Physical Therapy, 1999 - physicaltherapyjournal.org
... the manipulation, the type of injury sustained from the ... exposure, and the "dose"of
therapy complicate the assessment of risks and benefits associated with ...

Monoclonal antibody therapy for lymphoma -
P Campbell, R Marcus - Blood Reviews, 2003 - Elsevier
... with small numbers), suggesting that the observed benefit is sustained and based ...
than older patients and also more viable salvage therapy options, including ...

Strategies for the prevention of senile (type II) osteoporosis: an update -
S BOONEN, J DEQUEKER - Journal of Internal Medicine, 1996 - Blackwell Synergy
... rates of change showed a sustained benefit of calcium ... determined, and the sup- plemental
benefits of vitamin ... fractures were examined in 3270 elderly ambulatory ...

Adeno-associated Virus for Cancer Gene Therapy 1 -
S Ponnazhagan, DT Curiel, DR Shaw, RD Alvarez, GP … - Cancer Research, 2001 - AACR
... cells directly for increasing therapeutic benefit, targeting normal ... is becoming a
promising alternative in cancer therapy. ... that exert a sustained control over ...

Source: Google Scholar
 
 

Psoriatic arthritis, sustained benefits of Infliximab therapy

 
 
In the IMPACT ( Infliximab Multinational Psoriatic Arthritis Controlled Trial ) study, 104 patients with active psoriatic arthritis who had failed at least one DMARD ( disease-modifying antirheumatic drug ) were enrolled at nine centers in the United States, Canada and Europe.
Results demonstrated the safety and efficacy of Infliximab ( Remicade ) in treating this debilitating disorder.

The proportion of Infliximab-treated patients who achieved an ACR20 response at week 16 ( 65% ) was significantly higher than the proportion of placebo-treated patients who achieved this response ( 10% ).
In addition, 46% of Infliximab-treated patients achieved an ACR50 response, and 29% achieved an ACR70 response; no placebo-treated patient achieved these end points.

Among patients who had PASI scores of >/=2.5 at baseline, 68% of Infliximab-treated patients achieved improvement of >/=75% in the PASI score at week 16 compared with none of the placebo-treated patients.

Continued therapy with Infliximab resulted in sustained improvement in articular and dermatologic manifestations of psoriatic arthritis through week 50.

The incidence of adverse events was similar between the treatment groups.

Infliximab is a monoclonal antibody that specifically targets and irreversibly binds to TNF-alpha which has been shown to play a role in Crohn's disease, rheumatoid arthritis, ankylosing spondylitis and psoriasis, and may also be important in a wide range of other immune-mediated inflammatory disorders.

There are reports of serious infections, including tuberculosis and sepsis. Some of these infections have been fatal.
Remicade can lower the ability to fight infections.

In 2004, Centocor alerted U.S. healthcare professionals about hematologic and neurologic events that have occurred in patients being treated with Remicade.

The hematologic events, some of them fatal, have included leukopenia, neutropenia, thrombocytopenia and pancytopenia.
Although it's not clear that Remicade therapy causes these events and no high risk groups have been identified, Centocor advised practitioners to be cautious with patients who have significant hematologic abnormalities, or a history of these problems.

The company also informed that all patients on Remicade should be told to seek immediate medical attention if they develop signs suggestive of blood dyscrasias or infection, such as persistent fever, bruising or bleeding.
Practitioners should consider discontinuing Remicade therapy in patients who develop significant hematologic abnormalities.

The neurologic events have included rare cases of a central nervous system manifestation of systemic vasculitis.
Practitioners should consider discontinuing Remicade in patients who develop significant CNS reactions.

Source:

1) Arthritis & Rheumatism, 2005
2) FDA, 2004
 
 
 
Google
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page